ProMIS Neurosciences (PMN) 2026 Bloom Burton & Co. Healthcare Investor Conference summary

Operational and financial update

• Recently secured $175 million in financing, ensuring funding through the end of next year, led by major investors including Ally Bridge, Janus, and Wellington.

• Company is publicly listed on Nasdaq and maintains operations in Boston, Cambridge, and Vancouver.

• Fast track designation from the FDA was obtained last year for the lead Alzheimer's program.

• Actively planning for both internal funding and potential pharma partnerships for future phase III trials.

• Management team includes leaders with extensive CNS and neurodegenerative disease experience.

Platform and scientific differentiation

• Proprietary platform enables design of highly selective antibodies targeting misfolded proteins, using computational and AI-driven approaches.

• Lead asset, PMN310, targets toxic amyloid beta oligomers in Alzheimer's, avoiding plaque and monomer binding.

• Differentiation from competitors centers on selective targeting, aiming to reduce ARIA side effects seen with current drugs.

• In-house studies confirm PMN310 does not bind plaque, unlike other marketed antibodies.

• Pipeline includes candidates for ALS (TDP-43) and Parkinson’s/Lewy body dementia (alpha-synuclein).

Clinical development and trial progress

• Phase I-B trial in Alzheimer's is fully enrolled with 144 patients, exceeding initial targets due to strong site and patient interest.

• Study is placebo-controlled, double-blind, with three ascending dose cohorts and robust clinical and biomarker endpoints.

• Interim blinded analysis focused on safety and biomarker trends is expected early Q3, with top-line results in early Q1 next year.

• Phase I-A in healthy volunteers showed safety, tolerability, and sufficient blood-brain barrier penetration.

• Planning to accelerate SubQ formulation development and design phase III registration study based on phase I-B outcomes.